SCHEMBL23491364

SCHEMBL23491364

CCCCCCc1cncc(C=N)c1N

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR8 Q9NR97 9/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ USP2 O75604 2/20 0.34
▸ GAA P10253 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ GLA P06280 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CASP1 P29466 1/20 0.33
▸ CASP7 P55210 1/20 0.33
▸ GPR84 Q9NQS5 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ LIPG Q9Y5X9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27624960 0.83 ALDH1A1 (0.41) TLR8ALDH1A1KDM4EUSP2GAA
SCHEMBL27644997 0.75 GABRP (0.42) TLR8ALDH1A1KDM4EUSP2GAA
SCHEMBL19779244 0.71 DHFR (0.37) TLR8ALDH1A1KDM4EUSP2GAA
SCHEMBL9070349 0.69 THRA (0.39) MAPTMEN1KMT2ACYP3A4TDP1
SCHEMBL27645048 0.67 CYP2E1 (0.37) CYP3A4
SCHEMBL9639647 0.66 ESR1 (0.41) TLR8ALDH1A1KDM4EHSD17B10CYP3A4
SCHEMBL4295895 0.66 ESR1 (0.41) TLR8ALDH1A1KDM4EHSD17B10CYP3A4
SCHEMBL9810585 0.66 ESR1 (0.41) TLR8ALDH1A1KDM4EHSD17B10CYP3A4
SCHEMBL737293 0.65 PI4KA (0.43) TLR8ALDH1A1KDM4EUSP2GAA
SCHEMBL6665014 0.65 TDP1 (0.49) TLR8ALDH1A1KDM4EUSP2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171492-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171492-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 TLR8 2130/4885ALDH1A1 4626/4885KDM4E 4554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback